Achalla Lakshmi Sai Vijay, Shinde Raju K, Jogdand Sangita, Vodithala Sahitya
Department of Surgery, Acharya Vinoba Bhave Rural Hospital (AVBRH) Jawaharlal Nehru Medical College (JNMC) Datta Meghe Institute of Medical Sciences (DMIMS), Wardha, IND.
Department of General Surgery, Datta Meghe Institute of Medical Sciences (DMIMS) University, Wardha, IND.
Cureus. 2022 May 27;14(5):e25409. doi: 10.7759/cureus.25409. eCollection 2022 May.
Human epidermal growth factor receptor 2 (HER2/neu) is an oncogenic driver and a proven target for treatment of breast and gastric cancers. The role of HER2/neu and its blockage in various tumors, particularly colorectal adenocarcinoma has been widely explored following the revolutionary impact of anti-HER2/neu therapy in breast and gastric carcinoma patients. This review aimed to highlight the most recent updates on the significance of HER2/neu as a prognostic and predictive factor in these tumors together with its subsequent possible therapeutic indications from preclinical tests and ongoing assessments testing anti-HER2/neu agents in colorectal carcinoma (CRC). In the near future with a growingly tailored therapeutic approach toward cancers, HER2/neu targeted therapeutic strategies may blend into CRC treatment methods.
人表皮生长因子受体2（HER2/neu）是一种致癌驱动因子，也是治疗乳腺癌和胃癌的已证实靶点。在抗HER2/neu疗法对乳腺癌和胃癌患者产生革命性影响之后，HER2/neu及其阻断在各种肿瘤，尤其是结直肠癌中的作用得到了广泛研究。本综述旨在强调HER2/neu作为这些肿瘤的预后和预测因子的最新进展，以及其随后在临床前试验和正在进行的结直肠癌（CRC）抗HER2/neu药物评估中可能的治疗指征。在不久的将来，随着针对癌症的治疗方法越来越个性化，HER2/neu靶向治疗策略可能会融入CRC的治疗方法中。
